Journal
BONE MARROW TRANSPLANTATION
Volume 43, Issue 2, Pages 107-113Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/bmt.2008.296
Keywords
stem cell transplant; allo-hematopoietic cell transplantation; Ph plus ALL; imatinib; cardiac toxicity
Categories
Funding
- Children's Cancer Research
Ask authors/readers for more resources
The utility of imatinib in either the pre- or post-transplant period for Ph chromosome-positive (Ph +) ALL is uncertain. In addition, there have been recent concerns regarding imatinib and cardiac toxicity. We investigated the outcome of 32 patients with Ph + ALL who received an allo-hematopoietic cell transplant (HCT) at the University of Minnesota between 1999 and 2006. The median age at HCT was 21.9 years (range: 2.8-55.2). All patients were conditioned with CY and TBI. GVHD prophylaxis was CsA based. Of the 32 patients, 15 received imatinib therapy pre- or post-HCT (imatinib group) and 17 patients received either no imatinib (n = 11) or only after relapse (n 6) (non-imatinib group). Overall survival, relapse-free survival and relapse at 2 years was 61, 67 and 13% for the imatinib group as compared with 41, 35 and 35% for the non-imatinib group (P = 0.19, 0.12 and 0.20, respectively). Cardiac toxicity and TRM at 2 years were similar between groups. Thus, patients treated with imatinib in either the pre- or post-transplant setting had trends toward improved outcomes and no increase in cardiac toxicity. We suggest that imatinib be included in the peri-transplant management of all patients with Ph + ALL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available